Trinity Biotech (TRIB) Narrows Q1 Loss as Rapid HIV Test Sales Rise

Trinity Biotech (TRIB) reported a narrowed first-quarter loss and increased revenue, driven by a significant rise in rapid HIV test sales. The diagnostic company posted a net loss of $0.01 per share for the quarter ended March 31, 2026, a substantial improvement from the $0.05 per share loss recorded in the same period last year. Total revenue for Q1 2026 reached $25.8 million, up from $24.7 million year-over-year. Sales of rapid HIV tests surged to $5.0 million in the first quarter of 2026, compared to $3.7 million in Q1 2025. This growth helped offset declines in other segments. Diabetes care revenue decreased to $10.1 million from $10.6 million, while clinical laboratory revenue also saw a slight dip, falling to $10.7 million from $10.4 million in the prior year. Looking ahead, Trinity Biotech projects second-quarter 2026 revenue to be between $26.0 million and $27.0 million. The company's performance highlights the increasing demand for its rapid diagnostic solutions.